Role of Dienogest in Endometriosis in Young Women

Introduction Endometriosis associated pelvic pain (EAPP) is the most common complaint of patients with endometriosis. Nearly, 70% of females with endometriosis present with EAPP while endometriomas are found in 17–44% of patients.

A short-term single centre study was carried out in 56 patients in the age group of 15–35 years with complaints of pain and diagnosed as endometriosis either by imaging studies and/or by laparoscopy was given dienogest 2 mg OD, and effect of treatment was seen as improvement of pain score over a period of 3 months. The effect of dienogest was also seen on size of endometrioma. Patients were followed up at 1 and 3 months.

and Discussion Out of 56 patients, 38 (67.8%) patients reported their pain relief within 2–5 days after starting dienogest. Out of 41 patients (73%) who had severe pain at enrollment, only 1 patient (1.79%) complained of severe pain at the end of 1 month with dienogest. Successful reduction in endometriotic cyst size (>50%) was seen in 3 patients (5.3%) at the end of 1 month with dienogest. Out of 56 patients, 41 patients (73.2%) had significant pain relief (>30%) at three months of treatment. At the end of 3 months, seven patients (12.5%) had significant cyst size reduction (>50%) with dienogest. No major side effects were noted.

Dienogest is well tolerated drug for endometriosis showing significant relief of pain. However, it was seen that though endometriomas did not grow during treatment, significant regression was uncommon. Similar content being viewed by others

Foti PV, Farina R, Palmucci S et al. Endometriosis: clinical features, MR imaging findings and pathologic correlation. Insights Imaging. 2018;9(2):149–72. Alcázar JL, García-Manero M. Ovarian endometrioma vascularization in women with pelvic pain. Fertil Steril. 2007;87(6):1271–6. Noventa M, Scioscia M, Schincariol M et al. Imaging modalities for diagnosis of deep pelvic endometriosis: comparison between trans-vaginal sonography, rectal endoscopy sonography and magnetic resonance imaging. A Head-to-Head Meta-Anal Diagn. 2019;9(4):225. Moura AP, Ribeiro HS, Bernardo WM et al. Accuracy of transvaginal sonography versus magnetic resonance imaging in the diagnosis of rectosigmoid endometriosis: systematic review and meta-analysis. PLoS ONE. 2019;14(4):e0214842. Guerriero S, Saba L, Pascual MA et al. Transvaginal ultrasound vs magnetic resonance imaging for diagnosing deep infiltrating endometriosis: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2018;51(5):586–95. Park SY, Kim SH, Chae HD et al. Efficacy and safety of dienogest in patients with endometriosis: a single-center observational study over 12 months. Clin Exp Reprod Med. 2016;43(4):215. Muzii L, Galati G, Di Tucci C et al. Medical treatment of ovarian endometriomas: a prospective evaluation of the effect of dienogest on ovarian reserve, cyst diameter, and associated pain. Gynecol Endocrinol. 2020;36(1):81–3. Petraglia F, Hornung D, Seitz C et al. Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment. Arch Gynecol Obstet. 2012;285(1):167–73. Ebert AD, Dong L, Merz M et al. Dienogest 2 mg daily in the treatment of adolescents with clinically suspected endometriosis: the VISanne study to assess safety in ADOlescents. J Pediatr Adolesc Gynecol. 2017;30(5):560–7. Schindler AE. Dienogest in long-term treatment of endometriosis. Int J Women’s Health. 2011;3:175. Techatraisak K, Hestiantoro A, Ruey S et al. Effectiveness of dienogest in improving quality of life in Asian women with endometriosis (ENVISIOeN): interim results from a prospective cohort study under real-life clinical practice. BMC Womens Health. 2019;19(1):68. Angioni S, Pontis A, Malune ME et al. Is dienogest the best medical treatment for ovarian endometriomas? Results of a multicentric case control study. Gynecol Endocrinol. 2020;36(1):84–6. Xholli A, Filip G, Previtera F et al. Modification of endometrioma size during hormone therapy containing dienogest. Gynecol Endocrinol. 2020;36(6):545–49. Andres MP, Mendes RF, Hernandes C et al. Hormone treatment as first line therapy is safe and relieves pelvic pain in women with bowel endometriosis. Einstein (São Paulo). 2019;17(2):1–6. Momoeda M, Harada T, Terakawa N et al. Long-term use of dienogest for the treatment of endometriosis. J Obstet Gynaecol Res. 2009;35(6):1069–76. Strowitzki T, Faustmann T, Gerlinger C et al. Safety and tolerability of dienogest in endometriosis: pooled analysis from the European clinical study program. Int J Women’s Health. 2015;7:393. De Paula AM, Lopes LA, Baracat EC et al. Dienogest in the treatment of endometriosis: systematic review. Arch Gynecol Obstet. 2015;292(3):523–9. Takaesu Y, Nishi H, Kojima J et al. Dienogest compared with gonadotropin-releasing hormone agonist after conservative surgery for endometriosis. J Obstet Gynaecol Res. 2016;42(9):1152–8. Lee SR, Yi KW, Song JY et al. Efficacy and safety of long-term use of Dienogest in women with ovarian Endometrioma. Reprod Sci. 2018;25(3):341–6. Funding None required. Author information Authors and Affiliations Corresponding author Ethics declarations Conflict of interest The author declare that they have no conflict of interest. Ethical Approval Ethical clearance for the study was taken from hospital ethics committee with number- TP (MD/MS) (97/2018)/IEC/PGIMER/RMLH 1930. (Attached as supplementary file). Informed Consent Written informed consent of all study subjects was taken. Additional information Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Rights and permissions About this article Cite this article Malik, R., Mann, M.K. Role of Dienogest in Endometriosis in Young Women. J Obstet Gynecol India 71, 522–529 (2021). https://doi.org/10.1007/s13224-021-01483-0 Received: Accepted: Published: Version of record: Issue date: DOI: https://doi.org/10.1007/s13224-021-01483-0